{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:18Z","timestamp":1790727318045,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00259-021-05632-5","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T20:02:17Z","timestamp":1637956937000},"page":"1595-1606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study"],"prefix":"10.1007","volume":"49","author":[{"given":"Madhav Prasad","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-5584","authenticated-orcid":false,"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,27]]},"reference":[{"key":"5632_CR1","unstructured":"Lloyd RV, Osamura RY, Kl\u00f6ppel G &Rosai J. WHO classification of tumours of endocrine organs. 2018."},{"key":"5632_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","volume":"38","author":"VL Martucci","year":"2014","unstructured":"VL Martucci K Pacak 2014 Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment Curr Probl Cancer 38 7 41 https:\/\/doi.org\/10.1016\/j.currproblcancer.2014.01.001","journal-title":"Curr Probl Cancer"},{"key":"5632_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.wneu.2011.03.026","volume":"77","author":"RE Lieberson","year":"2012","unstructured":"RE Lieberson JR Adler SG Soltys C Choi IC Gibbs SD Chang 2012 Stereotactic radiosurgery as the primary treatment for new and recurrent paragangliomas: is open surgical resection still the treatment of choice? World Neurosurg 77 745 761 https:\/\/doi.org\/10.1016\/j.wneu.2011.03.026","journal-title":"World Neurosurg"},{"issue":"8","key":"5632_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/hed.22976","volume":"35","author":"C Su\u00e1rez","year":"2013","unstructured":"C Su\u00e1rez JP Rodrigo CC B\u00f6deker  2013 Jugular and vagal paragangliomas: systematic study of management with surgery and radiotherapy Head Neck 35 8 1195 1204 https:\/\/doi.org\/10.1002\/hed.22976","journal-title":"Head Neck"},{"key":"5632_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00405-013-2384-5","volume":"271","author":"C Su\u00e1rez","year":"2014","unstructured":"C Su\u00e1rez JP Rodrigo WM Mendenhall  2014 Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy Eur Arch Otorhinolaryngol 271 23 34 https:\/\/doi.org\/10.1007\/s00405-013-2384-5","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"5632_CR6","doi-asserted-by":"publisher","first-page":"R291","DOI":"10.1530\/ERC-13-0223","volume":"20","author":"C Capatina","year":"2013","unstructured":"C Capatina G Ntali N Karavitaki AB Grossman 2013 The management of head-and-neck paragangliomas EndocrRelat Cancer 20 R291 R305 https:\/\/doi.org\/10.1530\/ERC-13-0223","journal-title":"EndocrRelat Cancer"},{"key":"5632_CR7","unstructured":"Pacak K, Tella SH. Pheochromocytoma and Paraganglioma. [Updated 2018 Jan 4]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK481899\/."},{"key":"5632_CR8","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1210\/jc.2013-1907","volume":"98","author":"S Hescot","year":"2013","unstructured":"S Hescot S Leboulleux L Amar D Vezzosi I Borget C Bournaud-Salinas  2013 One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma J Clin Endocrinol Metab 98 4006 4012 https:\/\/doi.org\/10.1210\/jc.2013-1907","journal-title":"J Clin Endocrinol Metab"},{"key":"5632_CR9","doi-asserted-by":"publisher","unstructured":"Huang H, Abraham J, Hung E, Steven Averbuch, Maria Merino, Seth M Steinberg, et al. Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer. 2008;113:2020\u201328. https:\/\/doi.org\/10.1002\/cncr.23812.","DOI":"10.1002\/cncr.23812"},{"key":"5632_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","volume":"15","author":"C Jimenez","year":"2013","unstructured":"C Jimenez E Rohren MA Habra T Rich P Jimenez M Ayala-Ramirez  2013 Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma Curr Oncol Rep 15 356 371 https:\/\/doi.org\/10.1007\/s11912-013-0320-x","journal-title":"Curr Oncol Rep"},{"key":"5632_CR11","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1530\/EJE-14-0113","volume":"171","author":"E Baudin","year":"2014","unstructured":"E Baudin MA Habra F Deschamps G Cote F Dumont M Cabanillas  2014 Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma Eur J Endocrinol 171 R111 R122 https:\/\/doi.org\/10.1530\/EJE-14-0113","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"5632_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1210\/er.2014-1026.10.1210\/er.2014-1026","volume":"35","author":"D Ta\u00efeb","year":"2014","unstructured":"D Ta\u00efeb A Kaliski CC Boedeker V Martucci T Fojo JR Adler Jr K Pacak 2014 Oct Current approaches and recent developments in the management of head and neck paragangliomas Endocr Rev 35 5 795 819 https:\/\/doi.org\/10.1210\/er.2014-1026.10.1210\/er.2014-1026","journal-title":"Endocr Rev"},{"key":"5632_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/cancers11101505","volume":"11","author":"S N\u00f6lting","year":"2019","unstructured":"S N\u00f6lting M Ullrich J Pietzsch CG Ziegler G Eisenhofer A Grossman  2019 Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine Cancers (Basel) 11 1505 https:\/\/doi.org\/10.3390\/cancers11101505","journal-title":"Cancers (Basel)"},{"key":"5632_CR14","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"S Gonias R Goldsby KK Matthay R Hawkins D Price J Huberty  2009 Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma J Clin Oncol 27 4162 4168 https:\/\/doi.org\/10.1200\/JCO.2008.21.3496","journal-title":"J Clin Oncol"},{"key":"5632_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"DA Pryma BB Chin RB Noto JS Dillon S Perkins L Solnes  2019 Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma J Nucl Med 60 623 630 https:\/\/doi.org\/10.2967\/jnumed.118.217463","journal-title":"J Nucl Med"},{"key":"5632_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"J Strosberg G El-Haddad E Wolin A Hendifar J Yao B Chasen  2017 NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumour s N Engl J Med. 376 125 35","journal-title":"N Engl J Med."},{"key":"5632_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13550-019-0484-y","volume":"9","author":"MP Yadav","year":"2019","unstructured":"MP Yadav S Ballal C Bal 2019 Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas EJNMMI Res 9 13","journal-title":"EJNMMI Res"},{"key":"5632_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/jso.24553","volume":"115","author":"K Nastos","year":"2017","unstructured":"K Nastos VTF Cheung C Toumpanakis S Navalkissoor AM Quigley M Caplin  2017 Peptide receptor radionuclide treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas J Surg Oncol 115 425 434 https:\/\/doi.org\/10.1002\/jso.24553","journal-title":"J Surg Oncol"},{"key":"5632_CR19","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","volume":"102","author":"G Kong","year":"2017","unstructured":"G Kong S Grozinsky-Glasberg MS Hofman J Callahan A Meirovitz O Maimon  2017 Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma J Clin Endocrinol Metab 102 3278 3287","journal-title":"J Clin Endocrinol Metab"},{"key":"5632_CR20","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"A Imhof P Brunner N Marincek M Briel C Schindler H Rasch  2011 Response, survival, and long-term toxicity after therapy with the radiolabelled somatostatin analogue [90Y-DOTA]-TOC in metastasised neuroendocrine cancers J Clin Oncol 29 2416 2423","journal-title":"J Clin Oncol"},{"issue":"6","key":"5632_CR21","doi-asserted-by":"publisher","first-page":"100171","DOI":"10.1016\/j.esmoop.2021.100171","volume":"14","author":"S Severi","year":"2021","unstructured":"S Severi A Bongiovanni M Ferrara S Nicolini F Mauro Di M Sansovini  2021 Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials ESMO Open. 14 6 100171","journal-title":"ESMO Open."},{"key":"5632_CR22","doi-asserted-by":"publisher","unstructured":"Baum RP, Zhang J, Schuchardt C, Mueller D, Maecke H. First-in-human study of novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy. J Nucl Med. 2021;5:jnumed.120.258889 https:\/\/doi.org\/10.2967\/jnumed.120.258889.","DOI":"10.2967\/jnumed.120.258889"},{"key":"5632_CR23","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1007\/s00259-014-2857-9","volume":"41","author":"C Kratochwil","year":"2014","unstructured":"C Kratochwil FL Giesel F Bruchertseifer W Mier C Apostolidis R Boll  2014 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience Eur J Nucl Med Mol Imaging 41 2106 2119","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5632_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","volume":"47","author":"S Ballal","year":"2020","unstructured":"S Ballal MP Yadav C Bal RK Sahoo M Tripathi 2020 Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety Eur J Nucl Med Mol Imaging 47 934 946","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5632_CR25","unstructured":"Delpassand E, Tworowska I, Torgue J, Shanoon F, Hurt J, Ranganathan D et al. First-in-human dose escalation of AlphaMedixTM for targeted alpha-emitter therapy of NETs. Journal of Nuclear Medicine May 2020, 61 (supplement 1) 41."},{"key":"5632_CR26","doi-asserted-by":"publisher","unstructured":"Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Theranostics. 2020; 10:9364\u201377. doi:https:\/\/doi.org\/10.7150\/thno.48107. Available from https:\/\/www.thno.org\/v10p9364.htm.","DOI":"10.7150\/thno.48107"},{"issue":"supplement 1","key":"5632_CR27","first-page":"19","volume":"62","author":"CS Bal","year":"2021","unstructured":"CS Bal S Ballal MP Yadav 2021 Long-term outcome of 225Ac-DOTATATE targeted alpha therapy in patients with metastatic gastroenteropancreatic neuroendocrine tumors J Nucl Med 62 supplement 1 19","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"5632_CR28","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumour s J Nucl Med 50 Suppl 1 122S S150","journal-title":"J Nucl Med"},{"key":"5632_CR29","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Publish Date: November 27, 2017."},{"key":"5632_CR30","unstructured":"Fayers PM, Aaronson NK, Bjordal K, On behalf of the EORTC Quality of Life Group, et al. The EORTC QLQ-C30 scoring manual (3rd edition). Brussels: European Organisation for Research and Treatment of Cancer; 2001."},{"key":"5632_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/BF00439229","volume":"5","author":"MT King","year":"1996","unstructured":"MT King 1996 The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30 Qual Life Res 5 555 567","journal-title":"Qual Life Res"},{"key":"5632_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/JCO.1999.17.3.1008","volume":"17","author":"K Bjordal","year":"1999","unstructured":"K Bjordal E Hammerlid M Ahlner-Elmqvist A Graeff de M Boysen JF Evensen  1999 Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35 J Clin Oncol 17 1008 1019","journal-title":"J Clin Oncol"},{"key":"5632_CR33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cen.14106","volume":"91","author":"S Satapathy","year":"2019","unstructured":"S Satapathy BR Mittal A Bhansali 2019 Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis Clin Endocrinol (Oxf) 91 718 727","journal-title":"Clin Endocrinol (Oxf)"},{"key":"5632_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12105-017-0803-4","volume":"11","author":"MD Williams","year":"2017","unstructured":"MD Williams 2017 Paragangliomas of the head and neck: an overview from diagnosis to genetics Head Neck Pathol 11 278 287","journal-title":"Head Neck Pathol"},{"key":"5632_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0029-1224771","volume":"19","author":"TY Colen","year":"2009","unstructured":"TY Colen FG Mihm TP Mason JB Roberson 2009 Catecholamine-secreting paragangliomas: recent progress in diagnosis and perioperative management Skull Base 19 377 385","journal-title":"Skull Base"},{"key":"5632_CR36","doi-asserted-by":"publisher","unstructured":"Kratochwil, C., Apostolidis, L., Rathke, H. Apostolidis C, Bicu F, Bruchertseifer F,\u00a0et al.\u00a0Dosing\u00a0225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.\u00a0Eur J Nucl Med Mol Imaging\u00a0(2021). https:\/\/doi.org\/10.1007\/s00259-021-05474-1.","DOI":"10.1007\/s00259-021-05474-1"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-021-05632-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-021-05632-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:19:41Z","timestamp":1744179581000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-021-05632-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,27]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["5632"],"URL":"https:\/\/doi.org\/10.1007\/s00259-021-05632-5","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,27]]},"assertion":[{"value":"5 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance received Ref. No IEC-517.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work has not been submitted elsewhere as a full article or is not under consideration to any other journal.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}